scispace - formally typeset
Open AccessJournal ArticleDOI

MYC regulates the antitumor immune response through CD47 and PD-L1

Reads0
Chats0
TLDR
MYC regulates the expression of two immune checkpoint proteins on the tumor cell surface: the innate immune regulator CD47 (cluster of differentiation 47) and the adaptive immune checkpoint PD-L1 (programmed death–ligand 1).
Abstract
The MYC oncogene codes for a transcription factor that is overexpressed in many human cancers. Here we show that MYC regulates the expression of two immune checkpoint proteins on the tumor cell surface: the innate immune regulator CD47 (cluster of differentiation 47) and the adaptive immune checkpoint PD-L1 (programmed death-ligand 1). Suppression of MYC in mouse tumors and human tumor cells caused a reduction in the levels of CD47 and PD-L1 messenger RNA and protein. MYC was found to bind directly to the promoters of the Cd47 and Pd-l1 genes. MYC inactivation in mouse tumors down-regulated CD47 and PD-L1 expression and enhanced the antitumor immune response. In contrast, when MYC was inactivated in tumors with enforced expression of CD47 or PD-L1, the immune response was suppressed, and tumors continued to grow. Thus, MYC appears to initiate and maintain tumorigenesis, in part, through the modulation of immune regulatory molecules.

read more

Citations
More filters
Journal ArticleDOI

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

TL;DR: As the molecular mechanisms of resistance to immunotherapy are elucidated, actionable strategies to prevent or treat them may be derived to improve clinical outcomes for patients.
Journal ArticleDOI

Tumour-associated macrophages as treatment targets in oncology

TL;DR: It is surmised that TAMs can provide tools to tailor the use of cytoreductive therapies and immunotherapy in a personalized medicine approach, and that TAM-focused therapeutic strategies have the potential to complement and synergize with both chemotherapy and immunotherapies.
Journal ArticleDOI

Regulation and Function of the PD-L1 Checkpoint

TL;DR: The roles of the PD-1-PD-L1 axis in cancer is reviewed, focusing on recent findings on the mechanisms that regulate PD-L 1 expression at the transcriptional, posttranscriptional, and protein level, to inform the design of more precise and effective cancer immune checkpoint therapies.
Journal ArticleDOI

TISIDB: an integrated repository portal for tumor-immune system interactions

TL;DR: A user-friendly web portal TISIDB is designed, which integrated multiple types of data resources in oncoimmunology, and biologists can cross-check a gene of interest about its role in tumor-immune interactions through literature mining and high-throughput data analysis.
Journal ArticleDOI

Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory

TL;DR: The findings show that exosomal PD-L1 represents an unexplored therapeutic target, which could overcome resistance to current antibody approaches, and is described as a potential new therapeutic target for cancer patients.
References
More filters
Journal ArticleDOI

Inflammation and cancer: back to Virchow?

TL;DR: A rationale for the use of cytokine and chemokine blockade, and further investigation of non-steroidal anti-inflammatory drugs, in the chemoprevention and treatment of malignant diseases is provided.
Journal ArticleDOI

Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

TL;DR: A unifying conceptual framework called “cancer immunoediting,” which integrates the immune system’s dual host-protective and tumor-promoting roles is discussed.
Journal ArticleDOI

Selective inhibition of BET bromodomains.

TL;DR: A cell-permeable small molecule (JQ1) that binds competitively to acetyl-lysine recognition motifs, or bromodomains is reported, establishing proof-of-concept for targeting protein–protein interactions of epigenetic ‘readers’, and providing a versatile chemical scaffold for the development of chemical probes more broadly throughout the b romodomain family.
Journal ArticleDOI

Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

TL;DR: It is proposed that intercrossing research in molecular immunology and increasing funding to guide research of combination of agents represent a path forward for the development of curative therapies for the majority of cancer patients.
Journal ArticleDOI

CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.

TL;DR: It is found that increased CD47 expression is an independent, poor prognostic factor that can be targeted on human AML stem cells with blocking monoclonal antibodies capable of enabling phagocytosis of LSC.
Related Papers (5)